共 203 条
[1]
Dizon DS(2016)Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology J Clin Oncol 34 987-1011
[2]
Krilov L(2015)Toxicities of immunotherapy for the practitioner J Clin Oncol 33 2092-2099
[3]
Cohen E(2014)Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 1020-1030
[4]
Gangadhar T(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454
[5]
Ganz PA(2014)Mitigating the toxic effects of anticancer immunotherapy Nat Rev Clin Oncol 11 91-99
[6]
Hensing TA(2015)Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2004-U2032
[7]
Hunger S(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
[8]
Krishnamurthi SS(2015)Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2006-2017
[9]
Lassman AB(2015)Anti-PD-1-related pneumonitis during cancer immunotherapy N Engl J Med 373 288-290
[10]
Markham MJ(2015)Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development Int J Radiat Oncol Biol Phys 91 1048-1056